Managing the IBD Patient: COVID-19 Vaccines and IBD Patients

Release date: December 28, 2020
Expiration date: December 28, 2021
Estimated time to complete activity: 60 minutes

 

 

 

PROGRAM OVERVIEW

Despite an increased understanding of inflammatory bowel diseases (IBD) pathophysiology and the introduction of corresponding targeted treatments with the potential to alter the disease’s natural history, clinical and endoscopic remission remain elusive for many patients. Several factors contribute to suboptimal outcomes, including an entrenched treatment paradigm that frequently results in prolonged use of ineffective medications, uncertainty about the safety and efficacy of medications, systemic barriers, and access challenges.

In order to effectively treat IBD, gastroenterologists and the multidisciplinary IBD team of clinicians need strong foundational knowledge of the broad range of therapeutic agents licensed for the induction and maintenance of disease control, and how to individualize their use for any given patient. Education is necessary to ensure that clinicians who manage patients with IBD are up-to-date on current management strategies, including the use of objective measures such as mucosal healing and deep remission; new and emerging therapies, particularly novel mechanisms of action and safety profiles; and recent data from clinical trials. Clinicians must be knowledgeable regarding the benefits of early intervention, top-down versus step-up approaches, strategies for attaining remission and reducing healthcare costs, and new treat-to-target recommendations for management. This program will reduce these gaps through a conversational-style venue that fosters deeper educational impact and ultimately improves patient care.

FACULTY

Aline Charabaty, MD AGAF
Johns Hopkins School of Medicine
Clinical Director, GI Division
Director, IBD Center
Johns Hopkins- Sibley Memorial Hospital
Washington, District of Columbia

Anita Afzali, MD, MPH, FACG
Associate Professor of Medicine
Medical Director, OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio

Freddy Caldera, DO, MS
IBD Specialist
University of Wisconsin Health
Madison, Wisconsin

Michael Chiorean, MD
Director, IBD Center of Excellence
Digestive Disease Institute
Virginia Mason Medical Center
Seattle, Washington

Peter D. R. Higgins, MD, PhD, MSc
Professor, Division of Gastroenterology
Director, IBD Program
Director, Ambulatory and Chronic Disease Clinical Trial Support Unit
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

Jami Kinnucan, MD
Assistant Professor of Medicine
Director, IBD Education
Assistant Program Director, Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Edward V. Loftus, Jr., MD
Consultant, Division of Gastroenterology and Hepatology
Professor of Medicine, Mayo Clinic College of Medicine
Co-Director, Advanced Inflammatory Bowel Disease Fellowship
Mayo Clinic
Rochester, Minnesota

Millie Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Dana Lukin, MD
Associate Professor of Clinical Medicine
Weill Cornell Medical College
Cornell University
Clinical Director of Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
Weill Cornell Medicine
New York, New York

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, Ohio

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, Illinois

TARGET AUDIENCE

This educational initiative has been designed for all members involved in the IBD-care continuum. Of those that will derive the most benefit from this program are gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician’s assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Illustrate the importance of patient-centered care in addressing burdens associated with IBD
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 28, 2020 through December 28, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education and Monday Night IBD. Integrity Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Live Participation on December 28, 2020:
Integrity Continuing Education, Inc. designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation from December 29, 2020 – December 28, 2021:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Aline Charabaty, MD AGAF
Consulting Fees: AbbVie, Janssen, Takeda
Speakers’ Bureaus: AbbVie, Takeda

Anita Afzali, MD, MPH, FACG
Consulting Fees: AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Pfizer, Inc., Takeda
Speakers’ Bureaus: AbbVie, Janssen, Pfizer, Inc., Takeda
Contract Research: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Takeda
Other: IBD Horizons

Freddy Caldera, DO, MS
Consulting Fees: GlaxoSmithKline, Takeda
Other: Sanofi

Michael Chiorean, MD
Consulting Fees: AbbVie, Arena, Bristol-Myers Squibb, Medtronic, Pfizer, Inc., Takeda
Speakers’ Bureaus: AbbVie, Janssen, Medtronic, Pfizer, Inc., Takeda

Peter D. R. Higgins, MD, PhD, MSc
Consulting Fees: AbbVie, Genentech, Lilly, Prime Medical Education
Contracted Research: AbbVie, Eli Lilly, Pfizer, Inc.

Jami Kinnucan, MD
Consulting Fees: Bristol-Myers Squibb, Genentech, Janssen, Pfizer, Inc.

Edward V. Loftus, Jr., MD
Consulting Fees: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Iterative Scopes, Janssen, Pfizer, Inc., Takeda
Contracted Research: AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer, Inc., Robarts Clinical Trials, Takeda, Theravance

Millie Long, MD, MPH
Consulting Fees: AbbVie, Gilead, Janssen, Pfizer, Inc., Prometheus, TARGET PharmaSolutions
Contracted Research: Pfizer, Inc., Takeda

Dana Lukin, MD
Consulting Fees: AbbVie, Abgenomics, Pfizer, Inc., Takeda
Other: AbbVie, Janssen, Kenneth Rainin Foundation, Takeda

Miguel Regueiro, MD
Consulting Fees: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Inc., Prometheus, Salix, Seres, Takeda, TARGET PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Inc., Takeda

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP
Consulting Fees: AbbVie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), Iterative Scopes, Janssen, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Inc., Prometheus Laboratories, Reistone, Takeda, Techlab, Inc.
Contracted Research: Takeda
Other: American College of Gastroenterology (Board of Trustees), Cornerstones Health, Inc. (Co-Founder, CEO), GoDuRn, LLC (Co-Founder)

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
  •  Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from AbbVie Inc. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

 

Continue to Pretest